Faron Pharmaceuticals Oy is a Finnish drug discovery and development company focused on acute trauma, cancer and inflammatory diseases. With a pipeline of drug development projects, the company's lead products include Traumakine, a recombinant human IFN beta-1a currently in Phase III clinical trial for the treatment of acute respiratory distress syndrome (ARDS), Clevegen, an immunotherapy candidate designed to prevent tumor growth and metastasis, and D-ARDS, a diagnostic tool to estimate ARDS severity and follow up on ARDS outcomes. Faron Pharmaceuticals Oy collaborates with MediCity unit of Turku University Medical School, and was founded in 2003 in Turku, Finland.
Faron's ticker is FARN
The company's shares trade on the LSE stock exchange
They are based in Turku, Finland
There are 11-50 employees working at Faron
It is https://www.faron.com/
Faron is in the Healthcare sector
Faron is in the Biotechnology industry
The following five companies are Faron's industry peers: